1,8-Naphthyridin-2-one Compounds for the Treatment of Autoimmune Diseases - Patent application

Abstract

The present invention relates to a compound of formula (I): TIFF2023503165000058.tif70169 (In the formula, R 1 ~R 3 , m and n are as defined herein) and their pharmaceutically acceptable salts, enantiomers or diastereomers, as well as compositions comprising and methods of using such compounds.

Description

[Technical field]

[0001] The present invention relates to organic compounds useful for therapy and / or prophylaxis in mammals, in particular antagonists of TLR7 and / or TLR8 and / or TLR9 useful for treating systemic lupus erythematosus or lupus nephritis. [Background technology]

[0002] FIELD OF THEINVENTION Autoimmune connective tissue diseases (CTDs) include the prototypic autoimmune syndromes such as systemic lupus erythematosus (SLE), primary Sjögren's syndrome (pSjS), mixed connective tissue disease (MCTD), dermatomyositis / polymyositis (DM / PM), rheumatoid arthritis (RA), and systemic sclerosis (SSc). Except for RA, no truly effective and safe therapy for patients is available. SLE is the prototypic CTD with a prevalence of 20-150 cases per 100,000, resulting in widespread inflammation and tissue damage in different organs, from commonly observed symptoms in the skin and joints to renal, lung, or cardiac failure. Traditionally, SLE has been treated with nonspecific anti-inflammatory or immunosuppressive drugs. However, long-term use of immunosuppressive drugs, such as corticosteroids, is only partially effective and is associated with undesirable toxicities and side effects. Belimumab is the only FDA-approved drug for lupus in the last 50 years, but its efficacy is only moderate and delayed in some SLE patients (Navarra, SV et al Lancet 2011,377,721). Other biologics, such as anti-CD20 mAb, mAbs against certain cytokines or soluble receptors of said cytokines, have failed in most clinical trials. Therefore, new therapies are needed that provide sustained improvement in a larger proportion of the patient population and are safer for long-term use in many autoimmune and autoinflammatory diseases.

[0003] Toll-like receptors (TLRs) are an important family of pattern recognition receptors (PRRs) that can initiate a wide range of immune responses in a wide variety of immune cells. As natural host defense sensors, endosomal TLR7, 8, and 9 recognize nucleic acids derived from viruses, bacteria, and specifically, TLR7 / 8 and TLR9 recognize single-stranded RNA (ssRNA) and single-stranded CpG-DNA, respectively. However, aberrant nucleic acid detection of TLR7, 8, and 9 is considered as a critical node in a wide range of autoimmune and autoinflammatory diseases (Krieg, AM et al. Immunol. Rev. 2007, 220, 251. Jimenez-Dalmaroni, MJ et al Autoimmun Rev. 2016, 15, 1. Chen, JQ, et al. Clinical Reviews in Allergy & Immunology 2016, 50, 1.). Anti-RNA and anti-DNA antibodies are well-established SLE diagnostic markers, and these antibodies can deliver both self-RNA and self-DNA to endosomes. Self-RNA complexes can be recognized by TLR7 and TLR8, whereas self-DNA complexes can cause activation of TLR9. Indeed, defects in the clearance of self-RNA and self-DNA from blood and / or tissues are evident in SLE (systemic lupus erythematosus) patients. TLR7 and TLR9 have been reported to be upregulated in SLE tissues and correlate with chronicity and activity of lupus nephritis, respectively. In B cells of SLE patients, TLR7 expression correlates with anti-RNP antibody production, whereas TLR9 expression correlates with IL-6 levels and anti-double-stranded DNA antibody levels. Consistently, in lupus mouse models, TLR7 is required for anti-RNA antibodies, and TLR9 is required for anti-nucleosome antibodies. Meanwhile, overexpression of TLR7 or human TLR8 in mice promotes autoimmunity and autoinflammation. Moreover, TLR8 activation specifically contributes to mDC / macrophage inflammatory cytokine secretion, neutrophil nematosis, induction of Th17 cells, and suppression of Treg cells.In addition to the described role of TLR9 in promoting B cell autoantibody production, activation of TLR9 by self-DNA in pDCs also leads to the induction of type I IFN and other inflammatory cytokines. Considering these roles of TLR9 in both pDCs and B cells, as an important contributor to the pathogenesis of autoimmune diseases, and as the widespread presence of self-DNA complexes that can easily activate TLR9 in many patients suffering from autoimmune diseases, it may be further beneficial to further block the self-DNA-mediated TLR9 pathway at the apex of inhibition of TLR7 and TLR8 pathways. Taken together, the TLR7, 8, and 9 pathways represent new therapeutic targets for the treatment of autoimmune and autoinflammatory diseases for which there are no effective steroid-free and non-cytotoxic oral drugs, and inhibiting all of these pathways from the top may provide satisfactory therapeutic effects. Therefore, the present inventors have invented oral compounds that target and suppress TLR7, TLR8, and TLR9 for the treatment of autoimmune and autoinflammatory diseases. Summary of the Invention

[0004] Summary of the Invention The present invention relates to compounds of formula (I) and (Ia): [ka] (In the formula, R 1 is C 1-6 is alkyl, R 2 is C 1-6 is alkyl, R 3 is (C 1-6 Alkoxy C 1-6 alkyl)piperazinyl, (C 1-6 Alkyl)2AminoC 1-6Alkoxy, 2,5-diazabicyclo[2.2.1]heptanyl, 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl, 3,8-diazabicyclo[3.2.1]octanyl, 3-oxa-9-azabicyclo[3.3.1]nonanyl, 5-oxa-2,8-diazaspiro[3.5]nonanyl, amino(C 1-6 alkoxy) piperidinyl, amino(C 1-6 alkoxy)pyrrolidinyl, amino(C 1-6 Alkyl)azetidinyl, amino(C 1-6 Alkyl) piperidinyl, amino (C 1-6 Alkyl)pyrrolidinyl, amino-1,4-oxazepanyl, aminohalopyrrolidinyl, aminopiperidinyl, C 1-6 Alkyl-2,6-diazaspiro[3.3]heptanyl, C 1-6 Alkylpiperazinyl, Morpholinyl C 3-7 cycloalkyl, piperazinyl, piperidinyl or pyrrolidinyl or a pharma- ceutically acceptable salt thereof.

[0005] Another object of the present invention relates to novel compounds of formula (I) or formula (Ia) and their preparation, medicaments based on the compounds according to the present invention and their preparation, the use of compounds of formula (I) as TLR7 antagonists and / or TLR8 antagonists and / or TLR9 antagonists, and their use for the treatment or prevention of systemic lupus erythematosus or lupus nephritis. Compounds of formula (I) or formula (Ia) show excellent TLR7 and / or TLR8 and / or TLR9 antagonistic activity. In addition, compounds of formula (I) or formula (Ia) also show good hPBMC, cytotoxicity, solubility, human microsome stability and SDPK profile, and low CYP inhibition. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0006] Detailed Description of the Invention definition "C 1-6The term "alkyl" refers to saturated straight or branched chain alkyl groups containing 1 to 6, especially 1 to 4, carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, etc. 1-6 "Alkyl" groups are methyl, ethyl, and n-propyl.

[0007] "C 3-7 The term "cycloalkyl" refers to a saturated carbocyclic ring containing 3 to 7 carbon atoms, especially 3 to 6 carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. 3-7 "Cycloalkyl" groups are cyclopropyl, cyclopentyl and cyclohexyl.

[0008] The terms "halogen" and "halo" are used interchangeably herein and refer to fluoro, chloro, bromo, or iodo.

[0009] "C 1-6 The term "alkoxy" refers to 1-6 It represents alkyl-O-.

[0010] The term "halopyrrolidinyl" refers to pyrrolidinyl substituted once, twice or three times with halogen. Examples of halopyrrolidinyl include, but are not limited to, difluoropyrrolidinyl and fluoropyrrolidinyl.

[0011] The term "pharmaceutically acceptable salt" means a salt that is not biologically or otherwise undesirable. Pharmaceutically acceptable salts include both acid addition salts and base addition salts.

[0012] The term "pharmaceutically acceptable acid addition salts" refers to pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and the like, and organic acids selected from the aliphatic, alicyclic, aromatic, aryl-containing aliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid.

[0013] The term "pharmaceutically acceptable base addition salt" refers to a pharmaceutically acceptable salt as formed with an organic or inorganic base. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperidine, piperidine, N-ethylpiperidine, and polyamine resins.

[0014] The term "pharmaceutical active metabolite" refers to a pharmacologically active product produced through metabolism in the body of a particular compound or its salt. After entering the body, most drugs become substrates for chemical reactions that can change the physical properties and biological effects of the substrate. These metabolic transformations usually affect the polarity of the compounds of the present invention and change the way the drug is distributed in and excreted from the body. However, in some cases, drug metabolism is required for therapeutic effect.

[0015] The term "therapeutically effective amount" refers to an amount of a compound or molecule of the invention that, when administered to a subject, (i) treats or prevents a particular disease, condition or disorder, (ii) reduces, ameliorates, or eliminates one or more symptoms of a particular disease, condition or disorder, or (iii) prevents or delays the onset of one or more symptoms of a particular disease, condition or disorder described herein. The therapeutically effective amount will vary depending on the compound, the disease state being treated, the severity of the disease being treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending physician or veterinarian, and other factors.

[0016] The term "pharmaceutical composition" refers to a combination or solution containing a therapeutically effective amount of an active pharmaceutical ingredient together with a pharmaceutically acceptable excipient to be administered to a mammal, e.g., a human, in need of the pharmaceutical composition.

[0017] TLR7 and / or TLR8 and / or TLR9 antagonists The present invention relates to a compound comprising: (i) a compound of formula (I): [ka] (In the formula, R 1 is C 1-6 is alkyl, R 2 is C 1-6 is alkyl, R 3 is (C 1-6 Alkoxy C1-6 alkyl)piperazinyl, (C 1-6 Alkyl)2AminoC 1-6 Alkoxy, 2,5-diazabicyclo[2.2.1]heptanyl, 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl, 3,8-diazabicyclo[3.2.1]octanyl, 3-oxa-9-azabicyclo[3.3.1]nonanyl, 5-oxa-2,8-diazaspiro[3.5]nonanyl, amino(C 1-6 alkoxy) piperidinyl, amino(C 1-6 alkoxy)pyrrolidinyl, amino(C 1-6 Alkyl)azetidinyl, amino(C 1-6 Alkyl) piperidinyl, amino (C 1-6 Alkyl)pyrrolidinyl, amino-1,4-oxazepanyl, aminohalopyrrolidinyl, aminopiperidinyl, C 1-6 Alkyl-2,6-diazaspiro[3.3]heptanyl, C 1-6 Alkylpiperazinyl, Morpholinyl C 3-7 cycloalkyl, piperazinyl, piperidinyl or pyrrolidinyl or a pharma- ceutically acceptable salt thereof.

[0018] Another embodiment of the present invention is a compound of formula (ii) (Ia): [ka] (In the formula, R 1 is C 1-6 is alkyl, R 2 is C 1-6 is alkyl, R 3 is (C 1-6 Alkoxy C 1-6 alkyl)piperazinyl, (C 1-6 Alkyl)2AminoC 1-6Alkoxy, 2,5-diazabicyclo[2.2.1]heptanyl, 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl, 3,8-diazabicyclo[3.2.1]octanyl, 3-oxa-9-azabicyclo[3.3.1]nonanyl, 5-oxa-2,8-diazaspiro[3.5]nonanyl, amino(C 1-6 alkoxy) piperidinyl, amino(C 1-6 alkoxy)pyrrolidinyl, amino(C 1-6 Alkyl)azetidinyl, amino(C 1-6 Alkyl) piperidinyl, amino (C 1-6 Alkyl)pyrrolidinyl, amino-1,4-oxazepanyl, aminohalopyrrolidinyl, aminopiperidinyl, C 1-6 Alkyl-2,6-diazaspiro[3.3]heptanyl, C 1-6 Alkylpiperazinyl, Morpholinyl C 3-7 cycloalkyl, piperazinyl, piperidinyl or pyrrolidinyl or a pharma- ceutically acceptable salt thereof.

[0019] A further embodiment of the present invention comprises (iii)R 1 is methyl or ethyl, R 2 is methyl, R 32-(dimethylamino)ethoxy, 2-(methoxymethyl)piperazin-1-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 2-methylpiperazin-1-yl, 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, 3-amino-1-piperidinyl, 3-amino-3-methyl-1-piperidinyl, 3-amino-3-methyl-azetidin-1-yl, 3-amino-3-methyl-pyrrolidin-1-yl, 3-amino-4-fluoro-pyrrolidin-1-yl, 3-amino-4-methoxy-1-piperidinyl 3-amino-4-methoxy-pyrrolidin-1-yl, 3-methylpiperazin-1-yl, 3-oxa-9-azabicyclo[3.3.1]nonan-7-yl, 3-piperidinyl, 4-amino-3-methoxy-1-piperidinyl, 4-amino-4-methyl-1-piperidinyl, 4-morpholinocyclohexyl, 4-piperidinyl, 5-oxa-2,8-diazaspiro[3.5]nonan-2-yl, 5-oxa-2,8-diazaspiro[3.5]nonan-8-yl, 6-amino-1,4-oxazepan-4-yl, 6-methyl-2,6-diazaspiro[3.3]heptan-2-yl, piperazin-1-yl or pyrrolidin-3-yl; The compound of formula (I) or formula (Ia) according to (i) or (ii), or a pharma- ceutically acceptable salt thereof.

[0020] Further embodiments of the present invention include (iv) R 3 However, amino (C 1-6 alkoxy)pyrrolidinyl, amino(C 1-6 Alkyl) piperidinyl, amino-1,4-oxazepanyl, aminopiperidinyl, C 1-6 Alkyl-2,6-diazaspiro[3.3]heptanyl, C 1-6 Alkylpiperazinyl, C 1-6 Alkylpiperazinyl, Morpholinyl C 3-7A compound of formula (I) or (Ia) according to any one of (i) to (iii), or a pharma- ceutically acceptable salt thereof, wherein R is cycloalkyl, piperazinyl, piperidinyl or 3-oxa-9-azabicyclo[3.3.1]nonanyl.

[0021] A further embodiment of the present invention is a compound comprising: 3 is 3-amino-1-piperidinyl, 3-amino-3-methyl-1-piperidinyl, 3-amino-4-methoxy-pyrrolidin-1-yl, 3-methylpiperazin-1-yl, 4-amino-4-methyl-1-piperidinyl, 4-morpholinocyclohexyl, 4-piperidinyl, 6-amino-1,4-oxazepan-4-yl, 6-methyl-2,6-diazaspiro[3.3]heptan-2-yl, piperazin-1-yl or 3-oxa-9-azabicyclo[3.3.1]nonan-7-yl, or a pharma-ceutically acceptable salt thereof.

[0022] A further embodiment of the present invention comprises (vi)R 1 But, C 1-6 is alkyl, R 2 But, C 1-6 is alkyl, R 3 However, amino (C 1-6 alkoxy)pyrrolidinyl, amino(C 1-6 Alkyl) piperidinyl, amino-1,4-oxazepanyl, aminopiperidinyl, C 1-6 Alkyl-2,6-diazaspiro[3.3]heptanyl, C 1-6 Alkylpiperazinyl, C 1-6 Alkylpiperazinyl, Morpholinyl C 3-7 cycloalkyl, piperazinyl, piperidinyl or 3-oxa-9-azabicyclo[3.3.1]nonanyl; The compound of formula (I) or (Ia) according to any one of (i) to (v), or a pharma- ceutically acceptable salt thereof.

[0023] A further embodiment of the present invention comprises (vii)R 1 is methyl, R 2 is methyl, R 3 is 3-amino-1-piperidinyl, 3-amino-3-methyl-1-piperidinyl, 3-amino-4-methoxy-pyrrolidin-1-yl, 3-methylpiperazin-1-yl, 4-amino-4-methyl-1-piperidinyl, 4-morpholinocyclohexyl, 4-piperidinyl, 6-amino-1,4-oxazepan-4-yl, 6-methyl-2,6-diazaspiro[3.3]heptan-2-yl, piperazin-1-yl or 3-oxa-9-azabicyclo[3.3.1]nonan-7-yl, The compound of formula (I) or (Ia) according to any one of (i) to (vi), or a pharma- ceutically acceptable salt thereof.

[0024] Another embodiment of the present invention is a method for producing a composition comprising: 4-[(4R,10bS)-8-(3-amino-3-methyl-azetidin-1-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-(5-oxa-2,8-diazaspiro[3.5]nonan-2-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(3R)-3-amino-3-methyl-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(4aR,7aR)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(3R,4S)-3-amino-4-fluoro-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(3S,4S)-4-amino-3-methoxy-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(3S,4S)-3-amino-4-methoxy-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(2S)-2-(methoxymethyl)piperazin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-(5-oxa-2,8-diazaspiro[3.5]nonan-8-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-piperazin-1-yl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-[(3S)-3-methylpiperazin-1-yl]-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-[(3R)-3-methylpiperazin-1-yl]-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(3S)-3-amino-3-methyl-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(3R)-3-amino-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-[(2R)-2-methylpiperazin-1-yl]-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-(4-amino-4-methyl-1-piperidyl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[(6R)-6-amino-1,4-oxazepan-4-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-8-[2-(dimethylamino)ethoxy]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-(4-piperidyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-(3-piperidyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-pyrrolidin-3-yl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-(trans-4-morpholinocyclohexyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-(cis-4-morpholinocyclohexyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)-4-methyl-8-(endo-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, 4-[(4R,10bS)--4-methyl-8-(exo-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one, and 4-[(4R,10bS)-8-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-ethyl-1,8-naphthyridin-2-one or a pharma- ceutically acceptable salt, enantiomer or diastereomer thereof, selected from:

[0025] synthesis The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds and their starting materials are illustrated in the following schemes and examples. All substituents, particularly R 1 -R 6 are as defined above unless otherwise indicated. Further, unless expressly stated otherwise, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to one of ordinary skill in the art of organic chemistry.

[0026] A general synthetic route for preparing compounds of formula (I) is shown below in Scheme 1.

[0027] Scheme 1 [ka] where X and Y are halogens or leaving groups, such as OTf or OMs, and R 4 and R 5 is a protecting group, e.g., R 4 is Boc and R 5 is benzyl, and R 6 is alkylsilyl, for example trimethylsilyl.

[0028] Amide coupling of the protected amino acid (II) with the silylamine (III) can be achieved using coupling reagents such as HATU and DIPEA to give intermediate (IV). Selective deprotection affords R 4 After removal of , the amide bond of the resulting intermediate (V) can be reduced under reducing conditions, such as treatment with LAH, to give the diamine (VI). The imine (VIII), formed by condensation of the aldehyde (VII) with the diamine (VI) under typical dehydration conditions, can be cyclized under photoreduction conditions catalyzed by blue light and an Ir-based catalyst, such as [Ir(dtbbpy)(ppy)2][PF6], to give the tricyclic lactam (IX). Upon treatment with a reducing agent, such as LAH, the lactam (IX) can be reduced to a compound of formula (X). Compounds of formula (X) can be used as general intermediates for further functionalization under metal-catalyzed coupling conditions, such as Buchwald-Hartwig amination, Suzuki coupling, Negishi coupling, Stille coupling, or Pd-catalyzed C=O insertion. For example, compounds of formula (XI) can be produced from compounds of formula (X) under Buchwald-Hartwig amination conditions using a catalyst such as Ruphos Pd-G2 and a base such as Cs2CO3 (see: Acc. Chem. Res. 1998, 31, 805-818; Chem. Rev. 2016, 116, 12564-12649; Topics in Current Chemistry, 2002, 219, 131-209; and references cited therein). 5After selective deprotection of the groups (e.g., removal of benzyl protecting groups by hydrogenation over catalytic amounts of palladium on carbon), the resulting compound of formula (XII) can be subjected to aromatic nucleophilic substitution conditions (e.g., heating with halide (XIII) in the presence of DIEPA in DMSO) or Buchwald-Hartwig amination conditions (e.g., heating with halide (XIII) in the presence of a catalyst such as Ruphos Pd-G2 and a base such as Cs2CO3) to provide a compound of formula (I) or (Ia). In some embodiments, the compound of formula (XII) may contain a protecting group, e.g., Boc, which is removed prior to providing the final compound of formula (I) or (Ia).

[0029] Scheme 2 [ka]

[0030] Alternatively, selective deprotection can be used to give R 5 After removal of from formula (X), the resulting compound of formula (XIV) can be reacted with a halide (XIII) to give a compound of formula (XV) by nucleophilic aromatic substitution in the presence of a base such as DIEPA. Compounds of formula (I) or (Ia) can be obtained from compounds of formula (XV) via the following metal catalyzed coupling conditions: Buchwald-Hartwig amination conditions in the presence of a catalyst such as Ruphos Pd-G2 and a base such as Cs2CO3; R in the presence of a dichloromethane complex of tetrakis(triphenylphosphine)palladium(0) or [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) and a base such as potassium carbonate in a solvent. 3 -boronic acid or R 3-Suzuki coupling with a boronic ester; Stille coupling with an organotin reagent in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine)palladium(0); or Negishi coupling with an organozinc reagent in the presence of a palladium(0) catalyst such as tetrakis(triphenylphosphine)palladium(0) or [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II). In some embodiments, the compound of formula (XII) may contain a protecting group, e.g., Boc, which is removed prior to providing the final compound of formula (I) or (Ia).

[0031] The compounds of the invention may be obtained as mixtures of diastereomers or enantiomers, which may be separated by methods well known in the art, for example (chiral) HPLC or SFC.

[0032] The present invention also relates to a process for the preparation of a compound of formula (I) or formula (Ia), comprising the following steps: a) Formula (XII): [ka] and a compound of formula (XIII): [ka] substitution reaction or Buchwald-Hartwig amination of the compound; b) Formula (XV): [ka] Compounds of and amine HR 3 Buchwald-Hartwig amination reaction of Compound of formula (IX) and R 3 -boronic acid or R 3 Suzuki coupling reaction between -boronic esters The present invention also relates to a method, comprising any one of the steps:

[0033] Compounds of formula (I) or (Ia) when prepared by the above processes using achiral or chiral starting materials are also an object of the present invention.

[0034] Indications and Treatment Methods The present invention provides compounds that can be used as antagonists of TLR7 and / or TLR8 and / or TLR9, which inhibit the activation of pathways via TLR7 and / or TLR8 and / or TLR9, and the respective downstream biological events, including but not limited to innate and adaptive immune responses mediated via the production of all types of cytokines and all forms of autoantibodies.Thus, the compounds of the present invention are useful for blocking such receptor(s) in all types of cells that express TLR7 and / or TLR8 and / or TLR9, including but not limited to plasmacytoid dendritic cells, B cells, T cells, macrophages, monocytes, neutrophils, keratinocytes, epithelial cells.As such, the compounds can be used as therapeutic or prophylactic agents for systemic lupus erythematosus and lupus nephritis.

[0035] The present invention provides methods for the treatment or prevention of systemic lupus erythematosus and lupus nephritis in a patient in need thereof.

[0036] Another embodiment includes a method of treating or preventing systemic lupus erythematosus and lupus nephritis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I), a stereoisomer, tautomer, prodrug or a pharma- ceutically acceptable salt thereof. EXAMPLES

[0037] The present invention will be more fully understood by reference to the following examples, which should not, however, be construed as limiting the scope of the invention.

[0038] Abbreviation The present invention will be more fully understood by reference to the following examples, which should not, however, be construed as limiting the scope of the invention.

[0039] Abbreviations used herein are as follows: ACN: Acetonitrile DCM: dichloromethane DIPEA Diethylisopropylamine EA or EtOAc: Ethyl acetate FA: Formic acid HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate hr time hrs time I C 50 : 50% inhibitory concentration MS: Mass spectrometry prep-HPLC: Preparative High Performance Liquid Chromatography RT: retention time RuPhos Pd G2: Chloro(2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) 2nd generation SFC: Supercritical Fluid Chromatography TFA: Trifluoroacetic acid v / v volume ratio

[0040] General experimental conditions Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP1 system and Quad12 / 25 Cartridge module; ii) ISCO Combi Flash Chromatography Machine. Silica gel brand and pore size: i) KP-SIL 60 Å, particle size: 40-60 μm; ii) CAS registration number: Silica gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co.,Ltd, pore size: 200-300 or 300-400.

[0041] Intermediates and final compounds were purified by preparative HPLC on reversed-phase columns using XBridge™ Prep-C18 (5 μm, OBD™ 30×100 mm) columns, SunFire™ Prep-C18 (5 μm, OBD™ 30×100 mm) columns, Phenomenex Synergi-C18 (10 μm, 25×150 mm) or Phenomenex Gemini-C18 (10 μm, 25×150 mm) Waters AutoP purification system (sample manager 2767, pump 2525, detectors: Micromass ZQ and UV 2487, solvent system: ACN and 0.1% ammonium hydroxide in water; ACN and 0.1% FA in water or ACN and 0.1% TFA in water). or Gilson-281 purification system (Pump 322, Detector: UV 156, Solvent system: ACN and 0.05% ammonium hydroxide in water; ACN and 0.225% FA in water; ACN and 0.05% HCl in water; ACN and 0.075% TFA in water; or ACN and water).

[0042] For SFC chiral separations, intermediates were separated by chiral columns (Daicel chiralpak IC, 5 μm, 30 × 250 mm), AS (10 μm, 30 × 250 mm) or AD (10 μm, 30 × 250 mm) using a Mettler Toledo Multigram III system SFC, Waters 80Q preparative SFC or Thar80 preparative SFC, solvent system: CO2 and IPA (0.5% TEA in IPA) or CO2 and MeOH (0.1% NH3·H2O in MeOH), back pressure 100 bar, UV detection at 254 or 220 nm.

[0043] LC / MS spectra of the compounds were obtained using LC / MS (Waters™ Alliance 2795-Micromass ZQ, Shimadzu Alliance 2020-Micromass ZQ or Agilent Alliance 6110-Micromass ZQ), and the LC / MS conditions were as follows (run time 3 min or 1.5 min).

[0044] Acidic condition I: A: 0.1% TFA in HO, B: 0.1% TFA in ACN; Acidic condition II: A: 0.0375% TFA in HO, B: 0.01875% TFA in ACN; Basic condition I: A: 0.1% NH3·H2O in H2O, B: ACN; Basic condition II: A: 0.025% NH3·H2O in H2O, B: ACN; Neutral conditions: A: H2O; B: ACN.

[0045] Mass Spectra (MS): Generally, only ions representing parent masses are reported, and unless otherwise stated, the mass ions quoted are the positive mass ions (M−H) + It is.

[0046] NMR spectra were obtained using a Bruker Avance 400 MHz.

[0047] Microwave-assisted reactions were carried out in a Biotage Initiator Sixty microwave synthesizer. All reactions involving air-sensitive reagents were carried out under an argon or nitrogen atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted.

[0048] Preparation Examples The following examples are intended to illustrate the meaning of the present invention but are in no way limiting within the scope of the present invention.

[0049] Intermediate A (4R,10bS)-2-Benzyl-8-bromo-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindole [ka] The title compound was synthesized according to the following scheme. [ka]

[0050] Step 1: Preparation of tert-butyl N-[(1R)-2-[benzyl(trimethylsilylmethyl)amino]-1-methyl-2-oxo-ethyl]carbamate (Compound A2) To a solution of (2R)-2-(tert-butoxycarbonylamino)propanoic acid (compound A1, 10 g, 52.9 mmol) in DMF (40 mL) was added N-benzyl-1-(trimethylsilyl)methanamine (10.2 g, 52.9 mmol), HATU (20.1 g, 52.9 mmol) and DIEA (6.8 g, 9.2 mL, 52.9 mmol). The reaction mixture was stirred at room temperature overnight, then quenched with water (150 mL) and extracted three times with DCM (100 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to 30% EtOAc in PE) to give compound A2 (13.1 g, 68% yield). MS: calcd. 365 [(M+H) + ], measured value 365 [(M+H) + ].

[0051] Step 2: Preparation of (2R)-2-amino-N-benzyl-N-(trimethylsilylmethyl)propanamide (Compound A3) TFA (10 mL) was added to a solution of tert-butyl N-[(1R)-2-[benzyl(trimethylsilylmethyl)amino]-1-methyl-2-oxo-ethyl]carbamate (compound A2, 13.0 g, 35.7 mmol) in DCM (60 mL) and the mixture was stirred at room temperature for 4 h. The reaction was concentrated in vacuo and the residue was partitioned with saturated NaHCO3 (aq) and EA. The organic layer was separated and the basic aqueous layer was extracted twice with DCM (80 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give compound A3 (9.1 g, 96% yield) without further purification. MS: calculated 265 [(M+H) + ], measured value 265 [(M+H) + ].

[0052] Step 3: Preparation of (2R)-N1-benzyl-N1-(trimethylsilylmethyl)propane-1,2-diamine (Compound A4) To an ice-cold solution of (2R)-2-amino-N-benzyl-N-(trimethylsilylmethyl)-propanamide (compound A3, 9.0 g, 34 mmol) in anhydrous THF (100 mL) was added LiAlH4 (3.9 g, 102 mmol) slowly. After the addition was complete, the mixture was heated under reflux overnight. The reaction was cooled to room temperature and quenched with 20% NaOH (aq), then filtered and washed with EtOAc. The combined filtrate was concentrated in vacuo to give compound A4 (5.7 g, 67% yield) without further purification. MS: calcd 251 [(M+H) + ], measured value 251 [(M+H) + ].

[0053] Step 4: Preparation of (4R,10bS)-2-benzyl-8-bromo-4-methyl-1,3,4,10b-tetrahydropyrazino[1,2-b]isoindol-6-one (compound A6) A mixture of (2R)-N1-benzyl-N1-(trimethylsilylmethyl)propane-1,2-diamine (compound A4, 3 g, 12 mmol), methyl 5-bromo-2-formylbenzoate (2.9 g, 12 mmol), and 4A MS (5.0 g) in MeCN (80 mL) under N2 was stirred at room temperature overnight. The reaction was filtered through Celite and washed with DCM. The filtrate was concentrated in vacuo to give intermediate compound A5, and the residue was redissolved in MeCN / TFE (45 mL / 5 mL) followed by the addition of [Ir(dtbbpy)(ppy)2][PF6] (CAS: 676525-77-2, TCI, catalog: D4887, 42.9 mg, 46.9 μmol). The resulting mixture was stirred at room temperature for 2 days under exposure to blue LED (synLED-16 A Discover, 12W, wavelength 465-470nm, purchased from SYNLED corp). After the solvent was removed in vacuo, the residue was purified by flash chromatography (silica gel, 80g, 20%-70% EA in PE) to give compound A6 (1.85g, 42% yield). The stereochemistry was confirmed by NOESY. MS: calcd 371,373 [(M+H) + ], measured value 371,373 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 7.75(d,J=1.71Hz,1H)7.63(dd,J=8.01,1.77Hz,1H)7.19-7.35(m,6H)4.43(dd,J=10.88,3.67Hz,1H)3.67-3.86(m,1H) 3.56(s,2H)3.41-3.45(m,1H)2.79-2.87(m,1H)1.86(t,J=11.07Hz,1H)1.67(d,J=6.97Hz,3H)1.64(t,J=11.07Hz,1H).

[0054] Step 5: Preparation of (4R,10bS)-2-benzyl-8-bromo-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindole (Intermediate A) A mixture of (4R,10bS)-2-benzyl-8-bromo-4-methyl-1,3,4,10b-tetrahydropyrazino[1,2-b]isoindol-6-one (compound A6, 1.9 g, 5.0 mmol) and BH3 solution (1 M in THF, 40 mL, 40 mmol) was heated at 80 °C with stirring for 5 h. HCl solution (6N, 10 mL) was added slowly to the reaction mixture at 0 °C. The resulting mixture was stirred at room temperature overnight, and then the mixture was basified to pH 10 with NaOH solution (2N). The mixture was extracted twice with EtOAc. The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 30% to 100% EtOAc in PE) to give intermediate A (1.5 g, 85% yield). The stereochemistry was confirmed by NOESY. MS: calculated values ​​357 and 359 [(M+H) + ], measured values ​​357 and 359 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 7.49(s,1H)7.32-7.43(m,5H)7.26-7.32(m,1H)7.05(d,J=7.95Hz,1H)4.18(d,J=12.59Hz,1H)3.71(br d,J=10.51Hz,1H)3.55(dd,J=12.47,2.32Hz,1H)3.36-3.31(m,1H)2.97-2.89(m,1H)2. 77-2.87(m,1H)2.12(t,J=10.64Hz,1H)2.00(t,J=10.64Hz,1H)1.14(d,J=6.48Hz,3H).

[0055] Intermediate B 4-Chloro-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was synthesized according to the following scheme. [ka]

[0056] Step (a): Preparation of 2-(methylamino)pyridine-3-carboxylic acid (Compound B2) 2-Chloronicotinic acid (compound B1, 1.0 kg, 6.3 mol) was dissolved in a 33% solution of monomethylamine (386.3 mol) in ethanol. The reaction mixture was stirred in an autoclave at 80° C. for 80 hours and then concentrated in vacuo to give compound A2.2 (1.4 kg, crude). MS: calculated 153 [(M+H) + ], measured value 153 [(M+H) + ].

[0057] Step (b): Preparation of (1-methyl-2-oxo-1,8-naphthyridin-4-yl)acetate (Compound B3) A solution of 2-(methylamino)pyridine-3-carboxylic acid (compound B2, 1.4 kg, crude) in acetic anhydride (10.0 L, 105789 mmol) and acetic acid (5.0 L) was heated to reflux for 2 h. The reaction mixture was concentrated in vacuo to give compound B3 (1.8 kg, crude). MS: calculated 219 [(M+H) + ], measured value 219 [(M+H) + ].

[0058] Step (c): Preparation of 4-hydroxy-1-methyl-1,8-naphthyridin-2-one (Compound B4) To a solution of (1-methyl-2-oxo-1,8-naphthyridin-4-yl)acetate (compound B3, 1.8 kg, crude) in methanol (12.0 L) was added a solution of potassium carbonate (1.9 kg, 13.7 mol) in water (3.6 L). The mixture was stirred at 25° C. for 2 h. The reaction mixture was then concentrated under reduced pressure to remove MeOH. The residue was acidified to pH=4-5 with HCl solution (6N) and extracted three times with EA (1500 mL). The combined organic layers were washed with saturated brine (1500 mL), dried over Na2SO4, and concentrated in vacuo to give compound B4 (450 g, 40.2% yield). MS: calculated 177 [(M+H) + ], measured value 177 [(M+H) + ]; 1 H NMR(400MHz,DMSO-d6)δ ppm 11.68(s,1H),8.63(dd,J=4.60,1.80Hz,1H),8.22(dd,J=7.80,1.80Hz,1H),7.27(dd,J=7.80,4.60Hz,1H),5.93(s,1H),3.59(s,3H)

[0059] Step (d): Preparation of 4-chloro-1-methyl-1,8-naphthyridin-2-one (Intermediate A5) A solution of 4-hydroxy-1-methyl-1,8-naphthyridin-2-one (compound B4, 150 g, 0.85 mol) in phosphorus oxychloride (300 mL) was stirred at 100 °C for 2 h. The reaction mixture was concentrated under reduced pressure to remove phosphorus oxychloride. The residue was neutralized to pH = 7-8 by adding saturated aqueous NaHCO3 at room temperature, and the mixture was extracted twice with DCM (1000 mL). The combined organic layers were washed with saturated brine (500 mL), dried over Na2SO4, and concentrated in vacuo to give the crude product, which was purified by silica gel chromatography (PE / EtOAc = 1:0-7:1) to give intermediate B (39 g, 24% yield). MS: calculated 195 [(M+H) + ], measured value 195 [(M+H) + ]; 1 H NMR(400MHz,DMSO-d6)δ ppm 8.75(dd,J=4.60,1.60Hz,1H),8.32(dd,J=7.90,1.70Hz,1H),7.44(dd,J=8.00,4.60Hz,1H),7.03(s,1H),3.66(s,3H).

[0060] Intermediate C 4-Bromo-1-ethyl-1,8-naphthyridin-2-one [ka] The title compound was synthesized according to the following scheme. [ka]

[0061] Step (a): Preparation of 4-bromo-1-ethyl-1,8-naphthyridin-2-one (Intermediate C) To a solution of 4-bromo-1,8-naphthyridin-2(1H)-one (compound C1, 500 mg, 2.2 mmol) in DMF (20 mL) was added iodoethane (3.47 g, 22.2 mmol) and Cs2CO3 (1.45 g, 4.44 mmol). The reaction mixture was stirred at 80 °C overnight. After cooling to room temperature, the reaction was quenched by adding ice water (30 mL). The resulting mixture was extracted three times with PE / EA = 1 / 1 (30 mL). The combined organic layers were washed with saturated brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 12 g, 10% to 30% EA in PE) to give intermediate C (490 mg, 87% yield). MS: calculated 253 and 255 [(M+H) + ], measured values ​​253 and 255 [(M+H) + ].

[0062] Example 1 4-[(4R,10bS)-8-(3-amino-3-methyl-azetidin-1-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was synthesized according to the following scheme. [ka]

[0063] Step 1: Preparation of (4R,10bS)-8-bromo-4-methyl-1,2,3,4,6,10b-hexahydropyrazino[2,1-a]isoindole (compound 1.1) To a stirred solution of (4R,10bS)-2-benzyl-8-bromo-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindole (Intermediate A, 900 mg, 2.4 mmol) in DCE (30 mL) was added 1-chloroethyl carbonochloridate (1.7 g, 12.1 mmol) at room temperature. The reaction mixture was heated at reflux overnight and, after cooling to room temperature, was concentrated in vacuo. The residue was dissolved in MeOH (20 mL) and the resulting mixture was heated under reflux for an additional 2 h and then concentrated in vacuo. The residue was diluted with water (10 mL), the solution was basified with aqueous NaHCO3, and the mixture was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to give compound 1.1 (660 mg, 98% yield), which was used directly in the next step. MS: calculated 267 and 269 [(M+H) + ], measured values ​​267 and 269 [(M+H) + ].

[0064] Step 2: Preparation of 1-methyl-4-[(4R,10bS)-8-bromo-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1,8-naphthyridin-2-one (compound 1.2) To a solution of (4R,10bS)-8-bromo-4-methyl-1,2,3,4,6,10b-hexahydropyrazino[2,1-a]isoindole (compound 1.1, 0.70 g, 2.62 mmol) in DMSO (20 mL) was added CsF (1.19 g, 7.86 mmol) and 4-chloro-1-methyl-1,8-naphthyridin-2(1H)-one (intermediate B, 0.54 g, 2.75 mmol). The reaction mixture was stirred at 120° C. for 20 h. After cooling to room temperature, the reaction was quenched with water (50 mL) and extracted twice with DCM (50 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to 100% EtOAc in DCM) to give compound 1.2 (0.63 g, 56.5%). MS: calculated 425 and 427 [(M+H) +], measured values ​​425 and 427 [(M+H) + ].

[0065] Step 3: Preparation of tert-butyl N-[3-methyl-1-[(4R,10bS)-4-methyl-2-(1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]azetidin-3-yl]carbamate (compound 1.3) To a solution of 1-methyl-4-[(4R,10bS)-8-bromo-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1,8-naphthyridin-2-one (compound 1.2, 60 mg, 141 μmol) in toluene (8 mL), tert-butyl (3-methylazetidin-3-yl)carbamate (31.5 mg, 169 μmol), Cs2CO3 (138 mg, 423 μmol) and RuPhos Pd G2 (CAS: 1375325-68-0, Aldrich, catalog: 753246, 21.9 mg, 28.2 μmol) were added. The resulting mixture was heated at 100 °C for 20 h. After cooling to room temperature, it was diluted with water (50 mL) and extracted three times with DCM (50 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to 100% EtOAc in PE) to give compound 1.3 (40 mg, 53.4% ​​yield). MS: calculated 531 [(M+H) + ], measured value 531 [(M+H) + ].

[0066] Step 4: Preparation of 4-[(4R,10bS)-8-(3-amino-3-methyl-azetidin-1-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (Example 1) To a solution of tert-butyl N-[3-methyl-1-[(4R,10bS)-4-methyl-2-(1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]azetidin-3-yl]carbamate (compound 1.3, 40 mg, 75.4 μmol) in DCM (5 mL) was added TFA (2 mL). The reaction mixture was stirred at room temperature for 2 h and then concentrated to give the crude product, which was purified by preparative HPLC to give Example 1 (15 mg, 46.3% yield). MS: calculated 431 [(M+H) + ], measured value 431 [(M+H) + ]. 1 H NMR(400MHz, methanol-d4)δ ppm 8.75-8.59(m,1H),8.43-8.23(m,1H),7.48-7.37(m,1H),7.32(d,J=8. 3Hz,1H),6.68(d,J=1.7Hz,1H),6.60-6.48(m,1H),6.28(s,1H),5.15-5 .03(m,1H),4.81(d,J=13.6Hz,1H),4.49(d,J=13.6Hz,1H),4.26-4.11(m,1H),4.04(d,J=8.4Hz,2H),3.98-3.86(m,3H),3.78(s,3H),3.65(br d,J=13.1Hz,1H),3.20-3.08(m,1H),3.04-2.90(m,1H),1.70(s,3H),1.51(d,J=6.7Hz,3H).

[0067] Example 2 4-[(4R,10bS)-4-Methyl-8-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1 by using 2-methyl-2,6-diazaspiro[3.3]heptane (CAS: 1203567-11-6, PharmaBlock, catalog: PBLJ2831) instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate in step 3. Example 2 was obtained. MS: calculated value 457 [(M+H) + ], measured value 457 [(M+H) + ]. 1 H NMR (400MHz, methanol-d4) δ ppm 8.74-8.62 (m, 1H), 8.39-8.23 (m, 1H), 7.42-7.31 (m, 1H), 7.27 (d, J = 8.2Hz, 1H), 6.60 (d, J = 1.7Hz, 1H), 6.54-6.43 (m, 1H), 6.26 (s, 1H), 5.05-4.95 (m, 1H), 4.76 (d, J = 13.6Hz, 1H) ,4.50-4.30(m,5H),4.12-4.08(m,1H),4.08(s,4H),3.93-3.86(m,1H),3.77(s,3H),3.6 6-3.55(m,1H),3.15-3.05(m,1H),3.01-2.88(m,1H),2.94(s,3H),1.47(d,J=6.7Hz,3H).

[0068] Example 3 4-[(4R,10bS)-4-Methyl-8-(5-oxa-2,8-diazaspiro[3.5]nonan-2-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl 5-oxa-2,8-diazaspiro[3.5]nonane-8-carboxylate (CAS:1251005-61-4, PharmaBlock, catalog PBN20111065) instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate in step 3. Example 3 was obtained. MS: calculated value 473 [(M+H)+ ], measured value 473 [(M+H) + ]. 1 H NMR (400MHz, methanol-d4) δ ppm 8.74-8.65(m,1H),8.44-8.27(m,1H),7.46-7.36(m,1H),7.33(d,J=8.3Hz,1 H),6.67(d,J=1.7Hz,1H),6.63-6.51(m,1H),6.29(s,1H),5.19-5.08(m,1H) ,4.85(d,J=13.7Hz,1H),4.54(d,J=13.7Hz,1H),4.29-4.14(m,1H),4.08(d, J=8.6Hz,2H),4.01-3.88(m,3H),3.82(d,J=8.4Hz,2H),3.78(s,3H),3.66(br d,J=13.1Hz,1H),3.54(s,2H),3.30-3.24(m,2H),3.21-3.11(m,1H),3.05-2.95(m,1H),1.52(d,J=6.6Hz,3H).

[0069] Example 4 4-[(4R,10bS)-8-[(3R)-3-amino-3-methyl-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1, except that in step 3, tert-butyl N-(3-methylazetidin-3-yl)carbamate was replaced with tert-butyl N-[(3R)-3-methylpyrrolidin-3-yl]carbamate (CAS: 167888-15-5, PharmaBlock, catalog: PBXA 3113). Example 4 was obtained. MS: calculated value 445 [(M+H) + ], measured value 445 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.74-8.65(m,1H), 8.44-8.35(m,1H), 7.47-7.36(m,1H), 7.32(d,J=8.3Hz,1H), 6.78(d,J=1.8Hz,1H), 6.72-6.59(m,1H), 6.29(s,1H), 5.07-4.99(m,1H), 4.79(d,J=13.6Hz,1H), 4.45(d,J=13.4Hz,1H), 4. 17-4.00(m,1H),3.99-3.87(m,1H),3.79(s,3H),3.71-3.57(m,3H),3.53-3.43(m,1H),3.39(d,J=10. 6Hz,1H),3.19-3.07(m,1H),3.06-2.90(m,1H),2.37-2.20(m,2H),1.60(s,3H),1.50(d,J=6.7Hz,3H).

[0070] Example 5 4-[(4R,10bS)-8-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1, except that in step 3, tert-butyl N-(3-methylazetidin-3-yl)carbamate was replaced with tert-butyl N-[3R,4R)-4-methoxypyrrolidin-3-yl]carbamate (CAS: 1932066-52-8, PharmaBlock, catalog: PBZ4728). Example 5 was obtained. MS: calculated value 461 [(M+H) + ], measured value 461 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.73-8.68(m,1H), 8.49-8.28(m,1H), 7.43-7.36(m,1H), 7.29(d,J=8.3Hz,1H), 6.79(d,J=1.6Hz,1H), 6.68-6.62(m,1H), 6.28(s,1H), 4.83-4.75(m,1H), 4.68(d,J=13.2Hz,1H), 4.28 (d,J=13.2Hz,1H),4.19-4.07(m,1H),3.97-3.83(m,4H),3.80(s,3H),3.76-3.66(m,1H),3 .64-3.55(m,1H),3.52-3.41(m,2H),3.49(s,3H),3.09-2.91(m,2H),1.45(d,J=6.6Hz,3H).

[0071] Example 6 4-[(4R,10bS)-8-[(4aR,7aR)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] In step 3, the title compound was prepared in the same manner as in the preparation of Example 1, except that tert-butyl (4aR,7aR)-3,4a,5,6,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazine-4-carboxylate (CAS: 1932337-68-2, PharmaBlock, catalog: PBXA8123) was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 6 was obtained. MS: calculated value 473 [(M+H) + ], measured value 473 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.74-8.64(m,1H), 8.40-8.31(m,1H), 7.40-7.35(m,1H), 7.30(d,J=8.4Hz,1H), 6.72(d,J=1.8Hz,1H), 6.63-6.56(m,1H), 6.27(s,1H), 5.05-4.94(m,1H), 4.77(d,J=13.6Hz,1H), 4.42(d ,J=13.4Hz,1H),4.27-4.19(m,1H),4.15-3.84(m,4H),3.81-3.68(m,2H),3.77(s,3H),3.65- 3.34(m,5H),3.35-3.32(m,1H),3.13-3.05(m,1H),3.02-2.88(m,1H),1.47(d,J=6.7Hz,3H).

[0072] Example 7 4-[(4R,10bS)-8-[(3R,4S)-3-amino-4-fluoro-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl N-[(3R,4S)-4-fluoropyrrolidin-3-yl]carbamate (CAS: 1033718-91-0, PharmaBlock, catalog: PB09204) instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate in step 3. Example 7 was obtained. MS: calculated value 449 [(M+H) + ], measured value 449 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.74-8.60 (m, 1H), 8.40-8.30 (m, 1H), 7.44-7.37 (m, 1H), 7.34 (d, J = 8.3Hz, 1H), 6.79 (d, J = 1.5Hz, 1H), 6.71-6.59 (m, 1H), 6.29 (s, 1H), 5.62-5.41 (m, 1H), 5.12-5.03 (m, 1H), 4.82 (d,J=13.6Hz,1H),4.49(d,J=13.6Hz,1H),4.29-4.06(m,2H),3.98-3.61(m,5H),3.78(s ,3H),3.49(t,J=9.1Hz,1H),3.19-3.09(m,1H),3.07-2.93(m,1H),1.51(d,J=6.6Hz,3H).

[0073] Example 8 4-[(4R,10bS)-8-[(3S,4S)-4-amino-3-methoxy-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared in the same manner as in the preparation of Example 1, except that in step 3, tert-butyl N-[(3S,4S)-3-methoxy-4-piperidyl]carbamate (CAS: 907544-19-8, PharmaBlock, catalog: PB07429) was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 8 was obtained. MS: calculated value 475 [(M+H) + ], measured value 475 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.73-8.66(m,1H),8.46-8.31(m,1H),7.53-7.28(m,2H),7.19(d,J=2.0Hz,1H),7.15-7.03(m,1H),6.29(s,1H),5.22-5.14(m,1H),4.88(br d,J=13.7Hz,1H),4.58(d,J=13.7Hz,1H),4.35-4.11(m,2H),4.01-3.91(m,1H),3.88-3.80(m,1H),3.77(s,3H),3.66(br d,J=13.1Hz,1H),3.55(s,3H),3.47-3.36(m,1H),3.25-3.09(m,2H),3.08-2.96(m,1H),2.94 -2.80(m,1H),2.65-2.53(m,1H),2.25-2.11(m,1H),1.89-1.74(m,1H),1.54(d,J=6.7Hz,3H).

[0074] Example 9 4-[(4R,10bS)-8-[(3S,4S)-3-amino-4-methoxy-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared in the same manner as in the preparation of Example 1, except that in step 3, tert-butyl N-[(3S,4S)-4-methoxy-3-piperidyl]carbamate (PharmaBlock, catalog: PBZ5290) was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 9 was obtained. MS: calculated value 475 [(M+H) + ], measured value 475 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.76-8.61(m,1H),8.45-8.24(m,1H),7.46-7.33(m,2H),7.17(d,J=1.8Hz,1H),7.12-7.01(m,1H),6.29(s,1H),5.26-5.08(m,1H),4.86(br d,J=13.7Hz,1H),4.55(d,J=13.7Hz,1H),4.20(br s,1H),4.06-3.88(m,2H),3.84-3.73(m,1H),3.77(s,3H),3.69-3.58(m,1H),3.48-3.39(m,1H),3.47(s ,3H),3.29-3.09(m,2H),3.07-2.87(m,3H),2.48-2.29(m,1H),1.67-1.55(m,1H),1.52(d,J=6.7Hz,3H).

[0075] Example 10 4-[(4R,10bS)-8-[(2S)-2-(methoxymethyl)piperazin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl (3S)-3-(methoxymethyl)piperazine-1-carboxylate (CAS: 955400-16-5, Bide Pharmatech, catalog: BD293888) instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate in step 3. Example 10 was obtained. MS: calculated value 475 [(M+H) + ], measured value 475 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.73-8.65(m,1H),8.43-8.29(m,1H),7.41-7.30(m,2H),7.17(d,J=1.7Hz,1H),7.09-7.00(m,1H),6.28(s,1H),4.98-4.94(m,1H),4.77(br d,J=13.4Hz,1H),4.40(br d,J=13.4Hz,1H),4.28-4.17(m,1H),4.10-3.99(m,1H),3.98-3.87(m,1H),3.77(s,3H),3. 68-3.41(m,8H),3.30(s,3H),3.28-3.19(m,1H),3.13-2.93(m,2H),1.46(d,J=6.6Hz,3H).

[0076] Example 11 4-[(4R,10bS)-4-Methyl-8-(5-oxa-2,8-diazaspiro[3.5]nonan-8-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl 5-oxa-2,8-diazaspiro[3.5]nonane-2-carboxylate (CAS:1251011-05-8, PharmaBlock, catalog PBN20111063) instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate in step 3. Example 11 was obtained. MS: calculated value 473 [(M+H) + ], measured value 473 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.73-8.64(m,1H),8.40-8.30(m,1H),7.42-7.31(m,2H),7.16(d,J=1.7Hz,1H),7.11-7.00(m,1H),6.27(s,1H),5.01-4.94(m,1H) ),4.76(d,J=13.4Hz,1H),4.40(d,J=13.4Hz,1H),4.17-4.00(m,5H),3.96-3.90(m,1H),3.90-3.84(m,2H),3.77(s,3H),3.62(br d,J=12.8Hz,1H),3.40(s,2H),3.17-3.13(m,2H),3.12-2.94(m,2H),1.47(d,J=6.6Hz,3H).

[0077] Example 12 4-[(4R,10bS)-4-Methyl-8-piperazin-1-yl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1, by using tert-butyl piperazine-1-carboxylate instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate in step 3. Example 12 was obtained. MS: calculated value 431 [(M+H) + ], measured value 431 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.73-8.66 (m, 1H), 8.41-8.31 (m, 1H), 7.42-7.37 (m, 1H), 7.31 (d, J = 8.3 Hz, 1H), 7.16 (d, J = 1.8 Hz, 1H), 7.05-6.98 (m, 1H), 6.27 (s, 1H), 4.57 (br d,J=13.0Hz,2H),4.11(d,J=12.8Hz,1H),3.99-3.88(m,1H),3.82-3.69(m,1H),3.79( s,3H),3.61-3.54(m,1H),3.49-3.38(m,8H),3.03-2.89(m,2H),1.39(d,J=6.5Hz,3H).

[0078] Example 13 4-[(4R,10bS)-4-methyl-8-[(3S)-3-methylpiperazin-1-yl]-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1, except that in step 3, tert-butyl (2S)-2-methylpiperazine-1-carboxylate was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 13 was obtained. MS: calculated value 445 [(M+H) + ], measured value 445 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.77-8.62 (m, 1H), 8.40-8.27 (m, 1H), 7.40-7.28 (m, 2H), 7.17 (d, J = 1.8 Hz, 1H), 7.08-6.99 (m, 1H), 6.26 (s, 1H), 4.85-4.79 (m, 1H), 4.69 (d, J = 13.3 Hz, 1H), 4.30 (d, J = 13.2 Hz, 1H). H),3.98-3.71(m,4H),3.77(s,3H),3.64-3.56(m,1H),3.54-3.45(m,2H),3.34-3.25(m, 3H),3.11-2.93(m,3H),2.89-2.80(m,1H),1.44(d,J=6.7Hz,3H),1.41(d,J=6.6Hz,3H).

[0079] Example 14 4-[(4R,10bS)-4-methyl-8-[(3R)-3-methylpiperazin-1-yl]-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1, except that in step 3, tert-butyl (2R)-2-methylpiperazine-1-carboxylate was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 14 was obtained. MS: calculated value 445 [(M+H) + ], measured value 445 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.73-8.65 (m, 1H), 8.41-8.30 (m, 1H), 7.40-7.35 (m, 1H), 7.32 (d, J = 8.3Hz, 1H), 7.17 (d, J = 2.0Hz, 1H), 7.08-6.98 (m, 1H), 6.26 (s, 1H), 4.76-4.68 (m, 1H), 4.64 (d, J = 13.2Hz, 1H), 4.23 (d, J = 13.1Hz, 1H),3.96-3.90(m,1H),3.89-3.74(m,3H),3.78(s,3H),3.63-3.56(m,1H),3.55-3.42(m,2H),3.3 4-3.28(m,1H),3.11-2.92(m,3H),2.88-2.74(m,1H),1.42(d,J=6.7Hz,3H),1.40(d,J=6.6Hz,3H).

[0080] Example 15 4-[(4R,10bS)-8-[(3S)-3-amino-3-methyl-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1, except that in step 3, tert-butyl N-[(3S)-3-methyl-3-piperidyl]carbamate (CAS: 1363378-21-5, PharmaBlock, catalog: PBN20120294) was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 15 was obtained. MS: calculated value 459 [(M+H) + ], measured value 459 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.72-8.64(m,1H),8.40-8.31(m,1H),7.40-7.34(m,1H),7.32(d,J=8.3Hz,1H),7.19(d,J=1.8Hz,1H),7.10-6.98(m,1H),6.26(s, 1H),4.83-4.77(m,1H),4.68(d,J=13.2Hz,1H),4.29(d,J=13.1Hz,1H),3.97-3.86(m,2H),3.78(s,3H),3.65-3.58(m,1H),3.45(br d,J=12.8Hz,2H),3.06-2.93(m,2H),2.90(d,J=12.7Hz,2H),2.04-1.77(m,3H),1.72-1.68(m,1H),1.44(d,J=6.6Hz,3H),1.41(s,3H).

[0081] Example 16 4-[(4R,10bS)-8-[(3R)-3-amino-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl N-[(3R)-3-piperidyl]carbamate (CAS: 309956-78-3, PharmaBlock, catalog: PB00803) instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate in step 3. Example 16 was obtained. MS: calculated value 445 [(M+H) + ], measured value 445 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.70-8.64(m,1H),8.40-8.30(m,1H),7.47-7.32(m,2H),7.16(d,J=1.8Hz ,1H),7.08-6.99(m,1H),6.28(s,1H),5.19-5.07(m,1H),4.84(d,J=13.7H z,1H),4.53(d,J=13.7Hz,1H),4.25-4.09(m,1H),3.99-3.88(m,1H),3.76 (s,3H),3.69-3.60(m,1H),3.60-3.53(m,1H),3.52-3.42(m,1H),3.34(br d,J=3.3Hz,1H),3.20-3.07(m,3H),3.05-2.93(m,1H),2.10-1.90(m,2H),1.84-1.67(m,2H),1.51(d,J=6.7Hz,3H).

[0082] Example 17 4-[(4R,10bS)-4-methyl-8-[(2R)-2-methylpiperazin-1-yl]-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared in the same manner as in the preparation of Example 1, except that in step 3, tert-butyl (3R)-3-methylpiperazine-1-carbamate (CAS: 163765-44-4, PharmaBlock, catalog: PB07855) was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 17 was obtained. MS: calculated value 445 [(M+H) + ], measured value 445 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.75-8.64(m,1H),8.39-8.33(m,1H),7.43-7.32(m,2H),7.21(d,J=1.6Hz,1H),7.14-7.04(m,1H),6.28(s,1H),5.08-5 .01(m,1H),4.83(d,J=13.6Hz,1H),4.47(d,J=13.6Hz,1H),4.17-4.00(m,2H),3.99-3.90(m,1H),3.77(s,3H),3.65(br d,J=13.0Hz,1H),3.48-3.36(m,3H),3.29-3.18(m,3H),3.15-2.97(m,2H),1.48(d,J=6.7Hz,3H),1.10(d,J=6.6Hz,3H).

[0083] Example 18 4-[(4R,10bS)-8-(4-amino-4-methyl-1-piperidyl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared in a manner similar to that of Example 1, except that in step 3, tert-butyl N-(4-methyl-4-piperidyl)carbamate was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 18 was obtained. MS: calculated value 459 [(M+H) + ], measured value 459 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.70-8.65(m,1H), 8.40-8.29(m,1H), 7.47-7.29(m,2H), 7.15(d,J=1.8Hz,1H), 7.07-6.99(m,1H), 6.28(s,1H), 5.27-5.12(m,1H), 4.90(d,J=13.7Hz,1H), 4.59(d,J=13.7 Hz,1H),4.33-4.17(m,1H),4.11-3.83(m,1H),3.76(s,3H),3.69-3.50(m,3H),3.23-3 .09(m,3H),3.09-2.94(m,1H),2.01-1.85(m,4H),1.52(d,J=6.7Hz,3H),1.46(s,3H).

[0084] Example 19 4-[(4R,10bS)-8-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1, except that in step 3, tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (CAS: 113451-59-5, PharmaBlock, catalog: PBN20120579) was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 19 was obtained. MS: calculated value 443 [(M+H) + ], measured value 443 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.71-8.63(m,1H),8.38-8.32(m,1H),7.42-7.30(m,2H),6.83(s,1H),6.76-6.64(m,1H),6.2 7(s,1H),5.16-5.06(m,1H),4.86-4.68(m,2H),4.60-4.49(m,2H),4.27-4.11(m,1H),3.92(br d,J=11.2Hz,1H),3.79-3.72(m,1H),3.75(s,3H),3.64(br d,J=13.2Hz,1H),3.43-3.33(m,3H),3.23-3.11(m,1H),3.06-2.92(m,1H),2.29(br d,J=11.1Hz,1H),2.09(br d,J=11.1Hz,1H),1.51(d,J=6.7Hz,3H).

[0085] Example 20 4-[(4R,10bS)-8-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1, except that in step 3, tert-butyl (1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (CAS: 134003-84-2, PharmaBlock, catalog: PBN20120578) was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 20 was obtained. MS: calculated value 443 [(M+H) + ], measured value 443 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.74-8.63(m,1H),8.42-8.29(m,1H),7.43-7.32(m,2H),6.83(d,J=1.8Hz,1H),6.75-6.62(m,1H) ,6.27(s,1H),5.23-5.03(m,1H),4.84-4.69(m,2H),4.61-4.47(m,2H),4.31-4.09(m,1H),3.92(br d,J=12.7Hz,1H),3.82-3.70(m,1H),3.76(s,3H),3.65(br d,J=13.1Hz,1H),3.45-3.33(m,3H),3.23-3.09(m,1H),3.07-2.89(m,1H),2.29(br d,J=11.1Hz,1H),2.09(br d,J=11.1Hz,1H),1.51(d,J=6.7Hz,3H).

[0086] Example 21 4-[(4R,10bS)-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (CAS: 149771-44-8, PharmaBlock, catalog: PBN20120001) instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate in step 3. Example 21 was obtained. MS: calculated value 457 [(M+H) + ], measured value 457 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.59-8.53(m,1H),8.27-8.18(m,1H),7.30-7.22(m,1H),7.18(d,J=8.4Hz,1H),6.97(d,J=1. 8Hz,1H),6.88-6.77(m,1H),6.14(s,1H),4.63-4.56(m,1H),4.51(d,J=13.2Hz,1H),4.09(br t,J=6.3Hz,3H),3.84-3.76(m,1H),3.75-3.69(m,1H),3.66(s,3H),3.65-3.58(m,2H),3.46(br d,J=12.6Hz,1H),3.04(d,J=12.0Hz,2H),2.92-2.76(m,2H),2.03(s,4H),1.30(d,J=6.6Hz,3H).

[0087] Example 22 4-[(4R,10bS)-8-[(6R)-6-amino-1,4-oxazepan-4-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1 by using tert-butyl N-[(6R)-1,4-oxazepan-6-yl]carbamate (PharmaBlock, catalog: PB97932) instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate in step 3. Example 22 was obtained. MS: calculated value 461 [(M+H) + ], measured value 461 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.75-8.67(m,1H), 8.43-8.32(m,1H), 7.44-7.37(m,1H), 7.35(d,J=8.6Hz,1H), 7.03(d,J=2.0Hz,1H), 6.95-6.84(m,1H), 6.29(s,1H), 5.19-5.07(m,1H), 4.85(d,J=1 3.7Hz,1H),4.54(d,J=13.6Hz,1H),4.29-4.12(m,2H),4.09-3.74(m,6H),3.79(s,3 H),3.70-3.47(m,4H),3.22-3.10(m,1H),3.08-2.96(m,1H),1.52(d,J=6.7Hz,3H).

[0088] Example 23 4-[(4R,10bS)-8-[2-(dimethylamino)ethoxy]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 1, except that in step 3, 2-(dimethylamino)ethanol was used instead of tert-butyl N-(3-methylazetidin-3-yl)carbamate. Example 23 was obtained. MS: calculated value 434 [(M+H) + ], measured value 434 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.74-8.63(m,1H),8.37-8.28(m,1H),7.40-7.33(m,1H),7.28(d,J=8.3Hz,1H),7.11(d,J=2. 2Hz,1H),7.00-6.92(m,1H),6.25(s,1H),4.43(d,J=12.7Hz,1H),4.39-4.32(m,2H),4.30(br d,J=9.5Hz,1H),3.96-3.86(m,2H),3.79(s,3H),3.65-3.58(m,2H),3.56-3.42( m,2H),3.00(s,6H),2.96-2.86(m,1H),2.85-2.75(m,1H),1.32(d,J=6.4Hz,3H).

[0089] Example 24 4-[(4R,10bS)-4-methyl-8-(4-piperidyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was synthesized according to the following scheme. [ka]

[0090] Step 1: Preparation of tert-butyl 4-[(4R,10bS)-4-methyl-2-(1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (Compound 24.2) A solution of 4-[(4R,10bS)-8-bromo-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (compound 1.2, 300 mg, 705 μmol) in dioxane (18 mL) and water (2 mL) was added to tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (compound 24.1, 262 mg, 846 μmol), K2CO3 (195 mg, 1.41 mmol), and Pd(dppf)Cl2 . DCM adduct (51.6 mg, 70.5 μmol) was added. The resulting mixture was heated at 100° C. for 20 h. After cooling to room temperature, the reaction mixture was diluted with water (30 mL) and extracted twice with DCM (60 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to 100% EtOAc in DCM) to give compound 24.2 (240 mg, 64.5% yield). MS: calculated 528 [(M+H) + ], measured value 528 [(M+H) + ].

[0091] Step 2: Preparation of tert-butyl 4-[(4R,10bS)-4-methyl-2-(1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]piperidine-1-carboxylate (Compound 24.3) A mixture of tert-butyl 4-[(4R,10bS)-4-methyl-2-(1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (compound 24.2, 240 mg, 455 μmol) and Pd-C (30 mg) in MeOH (50 mL) was hydrogenated by a hydrogen balloon at room temperature for 30 min. After filtering off the catalyst, the filtrate was concentrated in vacuo. The crude material was purified by flash chromatography (silica gel, 40 g, 50% to 100% EtOAc in DCM) to give compound 24.3 (180 mg, 74.7% yield). MS: calculated 530 [(M+H) + ], Instant Wisdom Earth 530 [(M+H) + ].

[0092] Step 3: Preparation of 4-[(4R,10bS)-4-methyl-8-(4-piperidyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (Example 24) To a solution of tert-butyl 4-[(4R,10bS)-4-methyl-2-(1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]piperidine-1-carboxylate (compound 24.3, 180 mg, 340 μmol) in DCM (20 mL) was added TFA (5 mL). The reaction mixture was stirred at room temperature for 2 h and then concentrated to give the crude product, which was purified by preparative HPLC to give Example 24 (101 mg, 69.2% yield). MS: calculated 430 [(M+H) + ], measured value 430 [(M+H) + ]. 1H NMR(400MHz, methanol-d4)δ ppm 8.72-8.63(m,1H),8.39-8.29(m,1H),7.42-7.34(m,3H),7.31-7.23(m,1H),6.26(s,1H),4.78-4.71(m,1H) ,4.66(d,J=13.2Hz,1H),4.24(d,J=13.2Hz,1H),3.99-3.91(m,1H),3.88-3.82(m,1H),3.77(s,3H),3.59(br d,J=12.7Hz,1H),3.51(br d,J=12.6Hz,2H),3.23-3.09(m,2H),3.06-2.89(m,3H),2.12-2.03(m,2H),2.00-1.83(m,2H),1.41(d,J=6.6Hz,3H).

[0093] Example 25 4-[(4R,10bS)-4-methyl-8-(3-piperidyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 24 by using tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate instead of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate in step 1. Example 25 was obtained. MS: calculated value 430 [(M+H) + ], measured value 430 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.70-8.65(m,1H),8.38-8.33(m,1H),7.47-7.41(m,2H),7.40-7.30(m,2H), 6.27(s,1H),4.78-4.71(m,1H),4.74(d,J=13.3Hz,1H),4.36(d,J=13.3Hz,1 H),4.01-3.92(m,2H),3.77(s,3H),3.66-3.57(m,1H),3.48-3.36(m,2H),3. 15-2.96(m,5H),2.11-1.98(m,2H),1.95-1.78(m,2H),1.45(d,J=6.6Hz,3H).

[0094] Example 26 4-[(4R,10bS)-4-Methyl-8-pyrrolidin-3-yl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was prepared similarly to the preparation of Example 24 by using tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydropyrrole-1-carboxylate instead of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate carbamate in step 1. Example 26 was obtained. MS: calculated value 416 [(M+H) + ], measured value 416 [(M+H) + ]. 1H NMR (400MHz, methanol-d4) δ ppm 8.70-8.63(m,1H),8.38-8.30(m,1H),7.43-7.28(m,4H),6.25(s,1H),4.50(d,J=12.8Hz,1H),4.45(br d,J=10.0Hz,1H),4.01(br d,J=12.5Hz,1H),3.97-3.86(m,1H),3.78(s,3H),3.75-3.67(m,1H),3.63-3.52(m,4H ),3.44-3.33(m,1H),3.25-3.16(m,1H),2.99-2.91(m,1H),2.91-2.78(m,1H),2.46(br d,J=3.3Hz,1H),2.18-2.03(m,1H),1.34(d,J=6.4Hz,3H).

[0095] Example 27A and Example 27B 4-[(4R,10bS)-4-methyl-8-(trans-4-morpholinocyclohexyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one and 4-[(4R,10bS)-4-Methyl-8-(cis-4-morpholinocyclohexyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was synthesized according to the following scheme. [ka]

[0096] Step 1: Preparation of 4-[(4R,10bS)-8-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (Compound 27.2) To a solution of 4-[(4R,10bS)-8-bromo-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (compound 1.2, 100 mg, 235 μmol) in dioxane (9 mL) and water (1 mL), 2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (compound 27.1, 62.6 mg, 235 μmol), K2CO3 (65 mg, 470 μmol) and PdCl2(dppf).DCM adduct (17.2 mg, 23.5 μmol) were added. The resulting mixture was heated at 100° C. for 20 hours. After cooling to room temperature, the reaction mixture was diluted with water (30 mL) and extracted twice with DCM (60 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 20 g, 0% to 100% EtOAc in DCM) to give compound 27.2 (101 mg, 88.6% yield). MS: calculated 485 [(M+H) + ], measured value 485 [(M+H) + ].

[0097] Step 2: Preparation of 4-[(4R,10bS)-8-(1,4-dioxaspiro[4.5]decan-8-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (Compound 27.3) A mixture of 4-[(4R,10bS)-8-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (compound 27.2, 101 mg, 208 μmol) and Pd—C (20 mg) in ethyl acetate (30 mL) was hydrogenated at room temperature for 2 hours by a hydrogen balloon. After filtering off the catalyst, the filtrate was concentrated in vacuo to give compound 27.3 (90 mg, 88.7% yield), which was used directly in the next step without further purification. MS: calculated 487 [(M+H)+ ], measured value 487 [(M+H) + ].

[0098] Step 3: Preparation of 4-[(4R,10bS)-4-methyl-8-(4-oxocyclohexyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (Compound 27.4) To a solution of 4-[(4R,10bS)-8-(1,4-dioxaspiro[4.5]decan-8-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (compound 27.3, 90 mg, 185 μmol) in THF (10 mL) was added 2N HCl solution (aq, 2 mL, 4 mmol). The resulting mixture was stirred at reflux for 30 minutes. After cooling to room temperature, the reaction mixture was basified to pH 8 with 2N NaOH solution (aq) and extracted twice with EtOAc. The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo to give compound 27.4 (70 mg, 158 μmol, 85.5% yield), which was used directly in the next step without further purification. MS: Calculated 443 [(M+H) + ], measured value 443 [(M+H) + ].

[0099] Step 4: Preparation of 4-[(4R,10bS)-4-methyl-8-(trans-4-morpholinocyclohexyl)-3,4,6,10b-t tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one and 4-[(4R,10bS)-4-methyl-8-(cis-4-morpholinocyclohexyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (Example 27A and Example 27B) A mixture of 4-[(4R,10bS)-4-methyl-8-(4-oxocyclohexyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (compound 27.4, 70 mg, 158 μmol), morpholine (68.9 mg, 791 μmol) and NaBH3CN (19.9 mg, 316 μmol) in ethanol (5 mL) was refluxed with stirring for 2 hours. The mixture was concentrated and the residue was purified by preparative HPLC to give Example 27A (7.3 mg, 9% yield) and Example 27B (3.6 mg, 4.4% yield), whose stereochemistry was determined by NOESY.

[0100] Example 27 AMS: calculated value 514 [(M+H) + ], measured value 514 [(M+H) + ]. 1 H NMR (400 MHz, methanol-d4) δ ppm 8.65 (dd, J = 1.8, 4.6 Hz, 1H), 8.31 (dd, J = 1.8, 8.0 Hz, 1H), 7.34 (dd, J = 4.6, 8.1 Hz, 1H), 7.24 (s, 1H), 7.2-7.1 (m, 1H), 7.1-7.1 (m, 1H), 6.22 (s, 1H), 4.26 (d, J = 12.2 Hz, 1H), 4.02 (br d, J = 10.5 Hz, 1H), 3.89 (br d,J=11.6Hz,1H),3.77(s,3H),3.7-3.7(m,4H),3.7-3.6(m,1H),3.5-3.4(m,1H),3.26(ddd,J=3.0,6.8,10.0Hz,1H ),2.88(t,J=11.0Hz,1H),2.71(dd,J=10.5,12.0Hz,1H),2.7-2.6(m,4H),2.6-2.5(m,1H),2.4-2.3(m,1H),2.09(br d,J=11.1Hz,2H),1.94(br d,J=12.6Hz,2H),1.6-1.5(m,2H),1.5-1.4(m,2H),1.24(d,J=6.4Hz,3H).

[0101] Example 27 BMS: Calculated 514 [(M+H) + ], measured value 514 [(M+H) + ].1 H NMR(400MHz, methanol-d4)δ ppm 8.65(dd,J=1.8,4.6Hz,1H),8.31(dd,J=1.7,7.9Hz,1H),7.35(dd,J=4.6,8.0Hz,1H ),7.29(s,1H),7.16(d,J=0.7Hz,2H),6.22(s,1H),4.27(d,J=12.1Hz,1H),4.02(br d,J=10.4Hz,1H),3.9-3.8(m,1H),3.77(s,3H),3.72(t,J=4.7Hz,4H),3.67(dd,J=1.7,12.2Hz,1H), 3.5-3.4(m,1H),3.26(ddd,J=2.8,6.7,9.9Hz,1H),2.89(t,J=11.1Hz,1H),2.8-2.6(m,2H),2.50(br s,4H),2.3-2.2(m,1H),1.97(br d,J=11.5Hz,4H),1.6-1.6(m,4H),1.25(d,J=6.5Hz,3H).

[0102] Example 28A and Example 28B 4-[(4R,10bS)-4-methyl-8-(endo-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one and 4-[(4R,10bS)-4-methyl-8-(exo-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one [ka] The title compound was synthesized according to the following scheme. [ka]

[0103] Step 1: Preparation of tert-butyl 7-[(4R,10bS)-4-methyl-2-(1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-3-oxa-9-azabicyclo[3.3.1]non-6-ene-9-carboxylate (Compound 28.2) To a solution of 4-[(4R,10bS)-8-bromo-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (compound 1.2, 350 mg, 823 μmol) in dioxane (18 mL) and water (2 mL), tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dihydro-1H-pyrazino[2,1-a]isoindol-2-yl) was added. Oxaborolan-2-yl)-3-oxa-9-azabicyclo[3.3.1]nona-6-salt-9-carboxylate (CAS: 1313034-29-5, PharmaBlock, Cat: PB08083, 347 mg, 987 μmol), K2CO3 (227 mg, 1.65 mmol) and PdCl2(dppf).DCM adduct (60.2 mg, 82.3 μmol) were added. The resulting mixture was heated at 100 °C for 20 h. After cooling to room temperature, it was diluted with water (30 mL) and extracted twice with DCM (60 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 40 g, 0% to 100% EtOAc in DCM) to give compound 28.2 (310 mg, 75.6% yield). MS: Calculated value 570 [(M+H) + ], measured value 570 [(M+H) + ].

[0104] Step 2: Preparation of tert-butyl 7-[(4R,10bS)-4-methyl-2-(endo-1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (Compound 28.3) and tert-butyl 7-[(4R,10bS)-4-methyl-2-(exo-1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (Compound 28.4) A mixture of tert-butyl 7-[(4R,10bS)-4-methyl-2-(1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (compound 28.2, 310 mg, 544 μmol) and Pd—C (30 mg) in MeOH (50 mL) was hydrogenated with a hydrogen balloon at room temperature for 2 hours. After filtering off the catalyst, the filtrate was concentrated in vacuo and separated by SFC to give two single isomers: Compound 28.3 (32 mg, 10.3% yield) and Compound 28.4 (116 mg, 37.4% yield) with 50% ethanol (0.1% NH3H2O) / CO2 on an OX (5 μm, 250 × 20 mm i.d.) column. MS: calculated 572 [(M+H) + ], measured value 572 [(M+H) + The stereochemistry of Compound 28.3 and Compound 28.4 was determined by NOSEY.

[0105] Step 3: Preparation of 4-[(4R,10bS)-4-methyl-8-(endo-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (Example 28A) To a solution of tert-butyl 7-[(4R,10bS)-4-methyl-2-(endo-1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (compound 28.3, 30 mg, 52.4 μmol) in DCM (10 mL) was added TFA (5 mL). The reaction mixture was stirred at room temperature for 2 h and then concentrated to give the crude product, which was purified by preparative HPLC to give Example 28A (19 mg, 76.9% yield). MS: calculated 472 [(M+H) + ], measured value 472 [(M+H) + ]. 1 H NMR (400MHz, methanol-d4)δppm 8.68(dd,J=1.6,4.6Hz,1H),8.36(dd,J=1.7,7.9Hz,1H),7.48(s,1H),7.46-7.41(m,1H),7.41-7.34(m,2H),6.28(s,1H),4.99(dd,J=3.5, 10.9Hz,1H),4.79(d,J=13.3Hz,1H),4.43(d,J=13.4Hz,1H),4.21-3.92(m,7H),3.78(s,3H),3.68-3.57(m,3H),3.12-2.94(m,2H),2.29(br dd,J=1.9,8.3Hz,4H),1.47(d,J=6.6Hz,3H).

[0106] Step 4: Preparation of 4-[(4R,10bS)-4-methyl-8-(exo-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one (Example 28B) To a solution of tert-butyl 7-[(4R,10bS)-4-methyl-2-(exo-1-methyl-2-oxo-1,8-naphthyridin-4-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (compound 28.4, 40 mg, 69.9 μmol) in DCM (10 mL) was added TFA (5 mL). The reaction mixture was stirred at room temperature for 2 h and then concentrated to give the crude product, which was purified by preparative HPLC to give Example 28B (26 mg, 78.6% yield). MS: calculated 472 [(M+H) + ], measured value 472 [(M+H) + ]. 1 H NMR(400MHz, methanol-d4)δ ppm 8.80-8.53(m,1H),8.43-8.19(m,1H),7.47(s,1H),7.39-7.28(m,3H),6.26(s,1H),4.70- 4.56(m,2H),4.16(d,J=13.1Hz,1H),3.99-3.92(m,1H),3.90-3.82(m,4H),3.78-3.65(m,3 H),3.78(s,3H),3.61-3.52(m,1H),3.14-3.03(m,1H),3.00-2.87(m,2H),2.53-2.29(m,2H),2.22-1.94(m,2H),1.39(d,J=6.6Hz,3H).

[0107] Example 29 4-[(4R,10bS)-8-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-ethyl-1,8-naphthyridin-2-one [ka] The title compound was synthesized according to the following scheme. [ka]

[0108] Step 1: Preparation of tert-butyl N-[(3R,4R)-1-[(4R,10bS)-2-benzyl-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-4-methoxy-pyrrolidin-3-yl]carbamate (Compound 29.1) A solution of (4R,10bS)-2-benzyl-8-bromo-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindole (Intermediate A, 800 mg, 2.24 mmol) in dioxane (35 mL) was added with tert-butyl (((3R,4R)-4-methoxypyrrolidin-3-yl)carbamate (508 mg, 2.35 mmol), Cs2CO3 (2.19 g, 6.72 mmol) and XPhos Pd G2 (176 mg, 224 μmol) was added. The reaction mixture was stirred at 95° C. overnight. After cooling to room temperature, the mixture was diluted with water (30 mL) and extracted three times with EA (30 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 80 g, 50% to 100% EA in PE) to give compound 29.1 (870 mg, 79% yield). MS: calculated 493 [(M+H) + ], measured value 493 [(M+H) + ].

[0109] Step 2: Preparation of tert-butyl N-[(3R,4R)-1-[(4R,10bS)-4-methyl-1,2,3,4,6,10b-hexahydropyrazino[2,1-a]isoindol-8-yl]-4-methoxy-pyrrolidin-3-yl]carbamate (compound 29.2) A mixture of tert-butyl N-[(3R,4R)-1-[(4R,10bS)-2-benzyl-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-4-methoxy-pyrrolidin-3-yl]carbamate (compound 29.1, 650 mg, 1.32 mmol) and Pd(OH)2-C (100 mg) in MeOH (20 mL) was hydrogenated by hydrogen balloon at room temperature for 2 h. After filtering off the catalyst, the filtrate was concentrated in vacuo to give crude compound 29.2 (531 mg, 100% yield), which was used directly in the next step without further purification. MS: calculated 403 [(M+H) + ], measured value 403 [(M+H) + ].

[0110] Step 3: Preparation of tert-butyl N-[(3R,4R)-1-[(4R,10bS)-2-(1-ethyl-2-oxo-1,8-naphthyridin-4-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-4-methoxy-pyrrolidin-3-yl]carbamate (compound 29.3) To a solution of tert-butyl N-[(3R,4R)-1-[(4R,10bS)-4-methyl-1,2,3,4,6,10b-hexahydropyrazino[2,1-a]isoindol-8-yl]-4-methoxy-pyrrolidin-3-yl]carbamate (compound 29.2, 113 mg, 280 μmol) in dioxane (10 mL) was added 4-bromo-1-ethyl-1,8-naphthyridin-2-one (intermediate C, 71 mg, 280 μmol), Cs2CO3 (274 mg, 840 μmol) and RuPhos Pd G2 (22 mg, 28 μmol). The reaction mixture was stirred at 95 °C overnight. After cooling to room temperature, the mixture was diluted with water (30 mL) and extracted three times with EA (30 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography to give compound 29.3 (30 mg, 18.6% yield). MS: calculated 575 [(M+H) + ], measured value 575 [(M+H) + ].

[0111] Step 4: Preparation of 4-[(4R,10bS)-8-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-ethyl-1,8-naphthyridin-2-one (Example 29) To a solution of tert-butyl N-[(3R,4R)-1-[(4R,10bS)-2-(1-ethyl-2-oxo-1,8-naphthyridin-4-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-8-yl]-4-methoxypyrrolidin-3-yl]carbamate (compound 29.3, 30 mg, 52 μmol) in DCM (5 mL) was added 2,2,2-trifluoroacetic acid (2 mL). The reaction mixture was stirred at room temperature for 2 h and then concentrated to give the crude product, which was purified by preparative HPLC to give Example 29 (16 mg, 66.2% yield). MS: calculated 475 [(M+H) + ], measured value 475 [(M+H) + ]. 1 H NMR(400MHz, methanol-d4)δ ppm 8.60(dd,J=1.7,4.6Hz,1H),8.26(dd,J=1.6,8.1Hz,1H),7.32-7.23(m,2H),6.70(s,1H),6.65- 6.57(m,1H),6.18(s,1H),5.15-5.03(m,1H),4.84-4.80(m,1H),4.46(q,J=7.0Hz,3H),4.13(br d,J=1.2Hz,1H),4.06-3.99(m,1H),3.86-3.81(m,1H),3.77(dd,J=5.9,10.8Hz,1H),3.60(s,2H),3.37(s,4H),3.25(br d,J=3.3Hz,2H),3.14-2.79(m,2H),1.42(d,J=6.6Hz,3H),1.19(t,J=7.0Hz,3H).

[0112] Example 30 To determine the activity of the compounds of formula (I), (Ia) or (Ib) in the HEK293-Blue-hTLR-7 / 8 / 9 cell assay, the following test was performed.

[0113] HEK293-Blue-hTLR-7 Cell Assay: The stable HEK293-Blue-hTLR-7 cell line was purchased from InvivoGen (catalog number: hkb-htlr7, San Diego, CA, USA). These cells were originally designed to study the stimulation of human TLR7 by monitoring the activation of NF-κB. The SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of an IFN-beta minimal promoter fused to five NF-κB and AP-1 binding sites. SEAP was induced by activating NF-κB and AP-1 via stimulating HEK-Blue hTLR7 cells with TLR7 ligands. Thus, reporter expression was reduced by TLR7 antagonists under the stimulation of ligands such as R848 (Resiquimod) for 20 hours of incubation. The activity of the SEAP reporter in the cell culture supernatant was measured at a wavelength of 640 nm using the QUANTI-Blue™ kit (catalog number: rep-qb1, Invivogen, San Diego, Ca, USA), and the detection medium turned purple or blue in the presence of alkaline phosphatase.

[0114] HEK293-Blue-hTLR7 cells were incubated at a density of 250,000 to 450,000 cells / mL in a volume of 170 μL in a 96-well plate in Dulbecco's Modified Eagle's medium (DMEM) containing 4.5 g / L glucose, 50 U / mL penicillin, 50 mg / mL streptomycin, 100 mg / mL normocin, 2 mM L-glutamine, 10% (v / v) heat-inactivated fetal bovine serum, and 20 μL of test compound serially diluted in the presence of 1% final DMSO and 20 μM R848 in 10 μL of the above DMEM, and incubated at 37°C in a CO2 incubator for 20 hours. Then, 20 μL of supernatant from each well was incubated with 180 μL of Quanti-blue substrate solution at 37°C for 2 h, and the absorbance was read at 620-655 nm using a spectrophotometer. The signaling pathway in which TLR7 activation leads to downstream NF-κB activation has been widely accepted, and therefore, a similar reporter assay was modified to evaluate TLR7 antagonists.

[0115] HEK293-Blue-hTLR-8 Cell Assay: The stable HEK293-Blue-hTLR-8 cell line was purchased from InvivoGen (catalog number: hkb-htlr8, San Diego, CA, USA). These cells were originally designed to study the stimulation of human TLR8 by monitoring the activation of NF-κB. The SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of an IFN-beta minimal promoter fused to five NF-κB and AP-1 binding sites. SEAP was induced by activating NF-κB and AP-1 via stimulating HEK-Blue hTLR8 cells with TLR8 ligands. Thus, reporter expression was reduced by TLR8 antagonists under the stimulation of ligands such as R848 for 20 hours of incubation. The activity of the SEAP reporter in the cell culture supernatant was measured at a wavelength of 640 nm using the QUANTI-Blue™ kit (catalog number: rep-qb1, Invivogen, San Diego, California, USA), and the detection medium turned purple or blue in the presence of alkaline phosphatase.

[0116] HEK293-Blue-hTLR8 cells were incubated at a density of 250,000-450,000 cells / mL in a volume of 170 μL in a 96-well plate in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g / L glucose, 50 U / mL penicillin, 50 mg / mL streptomycin, 100 mg / mL normocin, 2 mM L-glutamine, 10% (v / v) heat-inactivated fetal bovine serum, with 20 μL of test compound serially diluted in the presence of 1% final DMSO and 10 μL of 60 μM R848 in the above DMEM, at 37° C. for 20 hours in a CO2 incubator. Then, 20 μL of supernatant from each well was incubated with 180 μL of Quanti-blue substrate solution for 2 hours at 37° C., and the absorbance was read at 620-655 nm using a spectrophotometer. The signaling pathway by which TLR8 activation leads to downstream NF-κB activation has become widely accepted, therefore a similar reporter assay was modified to evaluate TLR8 antagonists.

[0117] HEK293-Blue-hTLR-9 Cell Assay: The stable HEK293-Blue-hTLR-9 cell line was purchased from InvivoGen (catalog number: hkb-htlr9, San Diego, California, USA). These cells were originally designed to study the stimulation of human TLR9 by monitoring the activation of NF-κB. The SEAP (secreted embryonic alkaline phosphatase) reporter gene was placed under the control of an IFN-beta minimal promoter fused to five NF-κB and AP-1 binding sites. SEAP was induced by activating NF-κB and AP-1 via stimulating HEK-Blue hTLR9 cells with TLR9 ligands. Thus, reporter expression was reduced by TLR9 antagonists under the stimulation of ligands such as ODN2006 (catalog number: tlrl-2006-1, Invivogen, San Diego, California, USA) for 20 hours of incubation. The activity of the SEAP reporter in the cell culture supernatant was measured at a wavelength of 640 nm using the QUANTI-Blue™ kit (catalog number: rep-qb1, Invivogen, San Diego, California, USA), and the detection medium turned purple or blue in the presence of alkaline phosphatase.

[0118] HEK293-Blue-hTLR9 cells were incubated at a density of 250,000-450,000 cells / mL in a volume of 170 μL in a 96-well plate in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g / L glucose, 50 U / mL penicillin, 50 mg / mL streptomycin, 100 mg / mL normocin, 2 mM L-glutamine, 10% (v / v) heat-inactivated fetal bovine serum, with 20 μL of test compound serially diluted in the presence of 1% final DMSO and 10 μL of 20 μM ODN2006 in the above DMEM, and incubated for 20 hours at 37° C. in a CO2 incubator. Then, 20 μL of supernatant from each well was incubated with 180 μL of Quanti-blue substrate solution for 2 hours at 37° C., and the absorbance was read at 620-655 nm using a spectrophotometer. The signaling pathway by which TLR9 activation leads to downstream NF-κB activation has become widely accepted, therefore a similar reporter assay was modified to evaluate TLR9 antagonists.

[0119] The compounds of formula (I) have TLR7 and / or TLR8 inhibitory activity (IC 50 In addition, most of the compounds have TLR9 inhibitory activity of less than 0.4 μM. The activity data of the compounds of the present invention are shown in Table 1. [Table 1]

[0120] Example 31 Human microsome stability assay Human liver microsomes (Cat. No.: 452117, Corning, USA) were pre-incubated with test compounds in 100 mM potassium phosphate buffer (pH 7.4) for 10 min at 37°C. The reaction was initiated by adding an NADPH regenerating system. The final incubation mixture contained 1 μM test compound, 0.5 mg / mL liver microsomal protein, 1 mM MgCl2, 1 mM NADP, 1 unit / mL isocitrate dehydrogenase, and 6 mM isocitrate in 100 mM potassium phosphate buffer (pH 7.4). After 0, 3, 6, 9, 15, and 30 min incubation times at 37°C, the reaction was terminated by adding 300 μL of cold ACN (containing internal standard) to 100 μL of incubation mixture. After precipitation and centrifugation, 100 uL of supernatant was removed and 300 uL of water was added. The amount of compound remaining in the samples was measured by LC-MS / MS. Controls without NADPH regeneration at 0 and 30 min were also prepared and analyzed. Results were classified as low (<7.0 mL / min / kg), medium (7.0-16.2 mL / min / kg), and high (16.2-23.2 mL / min / kg). These results are summarized in Table 2. [Table 2]

[0121] Example 32 hERG channel inhibition assay The hERG channel inhibition assay is a highly sensitive measure to identify compounds that exhibit hERG inhibition associated with cardiotoxicity in vivo. + The channel was cloned in human and stably expressed in a CHO (Chinese Hamster Ovary) cell line. hERG The cells were used for patch clamp (voltage clamp, whole cell) experiments. The cells were stimulated with a voltage pattern to activate the hERG channel and induce I KhERG The cells were allowed to stabilize for several minutes, after which the I KhERGThe amplitude and kinetics of I was recorded at a stimulation frequency of 0.1 Hz (6 bpm). Increasing concentrations of test compound were then added to the preparation. For each concentration, an attempt was made to reach a steady-state effect, which was usually achieved within 3-10 min, at which point the next higher concentration was applied. KhERG The amplitude and kinetics of the responses were recorded at each drug concentration and compared to control values ​​(set at 100%). (Reference: Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.2003;Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.Cardiovasc.Res.58:32-45,Sanguinetti MC,Tristani-Firouzi M.2006;hERG potassium channels and cardiac arrhythmia.Nature 440:463-469,Webster R,Leishman D,Walker D.2002;Towards a drug concentration effect relationship for QT prolongation and torsades de pointes.Curr.Opin.Drug Discov. Devel. 5:116-26). The hERG results are shown in Table 3. [Table 3]

Claims

1. Formula (I): 【Chemistry 1】 (In the formula, R １ is C １－６ is alkyl; R ２ is C １－６ is alkyl; R ３ (C １－６ Alkoxy C １－６ (C alkyl)piperazinyl; １－６ Alkyl) ２ Amino C １－６ Alkoxy; 2,5-diazabicyclo[2.2.1]heptanyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3,8-diazabicyclo[3.2.1]octanyl; 3-oxa-9-azabicyclo[3.3.1]nonanyl; 5-oxa-2,8-diazaspiro[3.5]nonanyl; amino(C １－６ alkoxy) piperidinyl; amino (C １－６ alkoxy)pyrrolidinyl; amino(C １－６ alkyl)azetidinyl; amino(C １－６ alkyl) piperidinyl; amino (C １－６ Amino halopyrrolidinyl; Amino piperidinyl; C １－６ Alkyl-2,6-diazaspiro[3.3]heptanyl; C １－６ Alkylpiperazinyl; Morpholinyl C ３－７ cycloalkyl; piperazinyl; piperidinyl or pyrrolidinyl. or a pharma- ceutically acceptable salt thereof.

2. Formula (Ia): 【Chemistry 2】 (In the formula, R １ is C １－６ is alkyl; R ２ is C １－６ is alkyl; R ３ (C １－６ Alkoxy C １－６ (C alkyl)piperazinyl; １－６ Alkyl) ２ Amino C １－６ Alkoxy; 2,5-diazabicyclo[2.2.1]heptanyl; 3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazinyl; 3,8-diazabicyclo[3.2.1]octanyl; 3-oxa-9-azabicyclo[3.3.1]nonanyl; 5-oxa-2,8-diazaspiro[3.5]nonanyl; amino(C １－６ alkoxy) piperidinyl; amino (C １－６ alkoxy)pyrrolidinyl; amino(C １－６ alkyl)azetidinyl; amino(C １－６ alkyl) piperidinyl; amino (C １－６ Amino halopyrrolidinyl; Amino piperidinyl; C １－６ Alkyl-2,6-diazaspiro[3.3]heptanyl; C １－６ Alkylpiperazinyl; Morpholinyl C ３－７ cycloalkyl; piperazinyl; piperidinyl or pyrrolidinyl. or a pharma- ceutically acceptable salt thereof.

3. R １ is methyl or ethyl; R ２ is methyl; R ３ 2-(dimethylamino)ethoxy; 2-(methoxymethyl)piperazin-1-yl; 2,5-diazabicyclo[2.2.1]heptan-2-yl; 2-methylpiperazin-1-yl; 3,4,4a,5,7,7a-Hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl; 3,8-diazabicyclo[3.2.1]octan-3-yl; 3-amino-1-piperidinyl; 3-amino-3-methyl-1-piperidinyl; 3-amino-3-methyl-azetidin-1-yl; 3-amino-3-methyl-pyrrolidin-1-yl; 3-amino-4-fluoro-pyrrolidin-1-yl; 3-amino-4-methoxy-1-piperidinyl; 3-amino-4-methoxy-pyrrolidin-1-yl; 3-Methylpiperazin-1-yl; 3-Oxa-9-azabicyclo[3.3.1]nonan-7-yl; 3-piperidinyl; 4-amino-3-methoxy-1-piperidinyl; 4-amino-4-methyl-1-piperidinyl; 4-morpholinocyclohexyl; 4-piperidinyl; 3. The compound according to claim 1 or 2, which is 5-oxa-2,8-diazaspiro[3.5]nonan-2-yl; 5-oxa-2,8-diazaspiro[3.5]nonan-8-yl; 6-amino-1,4-oxazepan-4-yl; 6-methyl-2,6-diazaspiro[3.3]heptan-2-yl; piperazin-1-yl or pyrrolidin-3-yl, or a pharma- ceutically acceptable salt thereof.

4. R ３ But amino (C １－６ alkoxy)pyrrolidinyl; amino(C １－６ Alkyl) piperidinyl; amino-1,4-oxazepanyl; aminopiperidinyl; C １－６ Alkyl-2,6-diazaspiro[3.3]heptanyl; C １－６ Alkylpiperazinyl; C １－６ Alkylpiperazinyl; Morpholinyl C ３－７ 3. The compound of claim 1 or 2 which is cycloalkyl; piperazinyl; piperidinyl or 3-oxa-9-azabicyclo[3.3.1]nonanyl.

5. R ３ 3-amino-1-piperidinyl; 3-amino-3-methyl-1-piperidinyl; 3-amino-4-methoxy-pyrrolidin-1-yl; 3-Methylpiperazin-1-yl; 4-amino-4-methyl-1-piperidinyl; 4-morpholinocyclohexyl; 4-piperidinyl; The compound according to claim 4, which is 6-amino-1,4-oxazepan-4-yl; 6-methyl-2,6-diazaspiro[3.3]heptan-2-yl; piperazin-1-yl or 3-oxa-9-azabicyclo[3.3.1]nonan-7-yl.

6. R １ But, C １－６ is alkyl; R ２ But, C １－６ is alkyl; R ３ But amino (C １－６ alkoxy)pyrrolidinyl; amino(C １－６ Alkyl) piperidinyl; amino-1,4-oxazepanyl; aminopiperidinyl; C １－６ Alkyl-2,6-diazaspiro[3.3]heptanyl; C １－６ Alkylpiperazinyl; C １－６ Alkylpiperazinyl; Morpholinyl C ３－７ 3. The compound according to claim 1 or 2, which is cycloalkyl; piperazinyl; piperidinyl or 3-oxa-9-azabicyclo[3.3.1]nonanyl, or a pharma- ceutically acceptable salt thereof.

7. R １ is methyl; R ２ is methyl; R ３ 3-amino-1-piperidinyl; 3-amino-3-methyl-1-piperidinyl; 3-amino-4-methoxy-pyrrolidin-1-yl; 3-Methylpiperazin-1-yl; 4-amino-4-methyl-1-piperidinyl; 4-morpholinocyclohexyl; 4-piperidinyl; 7. The compound according to claim 6, which is 6-amino-1,4-oxazepan-4-yl; 6-methyl-2,6-diazaspiro[3.3]heptan-2-yl; piperazin-1-yl or 3-oxa-9-azabicyclo[3.3.1]nonan-7-yl, or a pharma- ceutically acceptable salt thereof.

8. 4-[(4R,10bS)-8-(3-amino-3-methyl-azetidin-1-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-(5-oxa-2,8-diazaspiro[3.5]nonan-2-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(3R)-3-amino-3-methyl-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(4aR,7aR)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(3R,4S)-3-amino-4-fluoro-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(3S,4S)-4-amino-3-methoxy-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(3S,4S)-3-amino-4-methoxy-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(2S)-2-(methoxymethyl)piperazin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-(5-oxa-2,8-diazaspiro[3.5]nonan-8-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-piperazin-1-yl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-[(3S)-3-methylpiperazin-1-yl]-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-[(3R)-3-methylpiperazin-1-yl]-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(3S)-3-amino-3-methyl-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(3R)-3-amino-1-piperidyl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-[(2R)-2-methylpiperazin-1-yl]-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-(4-amino-4-methyl-1-piperidyl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-(3,8-diazabicyclo[3.2.1]octan-3-yl)-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[(6R)-6-amino-1,4-oxazepan-4-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-8-[2-(dimethylamino)ethoxy]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-(4-piperidyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-(3-piperidyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-pyrrolidin-3-yl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-(trans-4-morpholinocyclohexyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-(cis-4-morpholinocyclohexyl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-(endo-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; 4-[(4R,10bS)-4-methyl-8-(exo-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-methyl-1,8-naphthyridin-2-one; and 4-[(4R,10bS)-8-[(3R,4R)-3-amino-4-methoxy-pyrrolidin-1-yl]-4-methyl-3,4,6,10b-tetrahydro-1H-pyrazino[2,1-a]isoindol-2-yl]-1-ethyl-1,8-naphthyridin-2-one or a pharma- ceutically acceptable salt, enantiomer or diastereomer thereof.

9. A process for the preparation of a compound according to any one of claims 1 to 8, comprising the following step c): c) Formula (XII): 【Chemistry 3】 and a compound of formula (XIII): 【Chemistry 4】 Substitution reaction or Buchwald-Hartwig amination of the compound of wherein Y is a halogen; １ ~R ３ is as defined in any one of claims 1 to 7) A method comprising:

10. A process for the preparation of a compound according to any one of claims 1 to 8, comprising the following step d): d) Formula (XV): 【Chemistry 5】 and the Buchwald-Hartwig amination reaction of the amine HR 3 wherein X is a halogen; and R 1 to R 3 are as defined in any one of claims 1 to 7. A method comprising:

11. A process for the preparation of a compound according to any one of claims 1 to 8, comprising the steps of: Formula (IX): 【Chemistry 6】 Suzuki coupling reaction between a compound of formula (I) and an R 3 -boronic acid or an R 3 -boronic ester wherein X is halogen; R 5 is benzyl; and R 2 to R 3 are as defined in any one of claims 1 to 7. A method comprising:

12. A compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt, enantiomer or diastereomer, for use as a therapeutically active substance.

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 and a therapeutically inert carrier.

14. The pharmaceutical composition according to claim 13 for the treatment or prevention of systemic lupus erythematosus or lupus nephritis.

15. Use of a compound according to any one of claims 1 to 8 for the preparation of a medicament for the treatment or prevention of systemic lupus erythematosus or lupus nephritis.

16. 14. A pharmaceutical composition according to claim 13 for use as a TLR7 or TLR8 or TLR9 antagonist.

17. 14. The pharmaceutical composition according to claim 13 for use as a TLR7 and TLR8 and TLR9 antagonist.

18. Use of a compound according to any one of claims 1 to 8 for the preparation of a medicament for a TLR7 and TLR8 and TLR9 antagonist.

19. A compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt, enantiomer or diastereomer, for the treatment or prevention of systemic lupus erythematosus or lupus nephritis.

Images